Circulating CD20 and CD52 in patients with non‐Hodgkin's lymphoma or Hodgkin's disease
暂无分享,去创建一个
J. Armitage | P. Bierman | J. Vose | K. Do | H. Kantarjian | T. Manshouri | M. Keating | S. O'brien | F. Giles | M. Albitar | Marcella M. Johnson | G. Bociek
[1] G. Weiner,et al. Monoclonal antibody therapy of B cell lymphoma , 2004, Expert opinion on biological therapy.
[2] K. Do,et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. , 2003, Blood.
[3] D. Podoloff,et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[4] K. Do,et al. Circulating CD 20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance , 2003 .
[5] Nils Lid Hjort,et al. Goodness‐of‐fit processes for logistic regression: simulation results , 2002, Statistics in medicine.
[6] M. Keating,et al. Emerging information on the use of rituximab in chronic lymphocytic leukemia. , 2002, Seminars in oncology.
[7] W. Wilson,et al. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R. , 2002, Seminars in oncology.
[8] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[9] Pierre Morel,et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[10] U. Jaeger,et al. Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study. , 2002, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[11] J. Vose,et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] A Domagała,et al. CD52 antigen--a review. , 2001, Medical science monitor : international medical journal of experimental and clinical research.
[13] M. Sliwkowski,et al. CD20: a gene in search of a function. , 2000, Seminars in oncology.
[14] S. O'brien,et al. High-dose rituximab therapy in chronic lymphocytic leukemia. , 2000, Seminars in oncology.
[15] P. Mclaughlin,et al. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. , 2000, Seminars in oncology.
[16] C. Kirchhoff,et al. New Insights into the Origin, Structure and Role of CD52: A Major Component of the Mammalian Sperm Glycocalyx , 2000, Cells Tissues Organs.
[17] B. Harms,et al. CD52 mRNA is modulated by androgens and temperature in epididymal cell cultures , 2000, Molecular reproduction and development.
[18] J. K. Hofmeister,et al. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. , 2000, Blood cells, molecules & diseases.
[19] Zhensheng Liu,et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. , 2000, Blood.
[20] M. C. Liu,et al. Extensive surface phenotyping of alveolar macrophages in interstitial lung disease. , 2000, Clinical immunology.
[21] H. Waldmann,et al. Structure and chromosomal location of mouse and human CD52 genes. , 1999, Biochimica et biophysica acta.
[22] W. Rowan,et al. Cross‐linking of the CAMPATH‐1 antigen (CD52) mediates growth inhibition in human B‐ and T‐lymphoma cell lines, and subsequent emergence of CD52‐deficient cells , 1998, Immunology.
[23] R. Levy,et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] P. Johnson,et al. The association between CD20 and Src-family Tyrosine kinases requires an additional factor. , 1998, Molecular Immunology.
[25] L. Ginaldi,et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. , 1998, Leukemia research.
[26] S. Robbins,et al. Rapid Redistribution of CD20 to a Low Density Detergent-insoluble Membrane Compartment* , 1998, The Journal of Biological Chemistry.
[27] K. Spiekermann,et al. Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. , 1996, Blood.
[28] G. Schieven,et al. Association of 75/80-kDa Phosphoproteins and the Tyrosine Kinases Lyn, Fyn, and Lck with the B Cell Molecule CD20 , 1995, The Journal of Biological Chemistry.
[29] J Hermans,et al. International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. , 1995, Blood.
[30] T. Tedder,et al. CD20: a regulator of cell-cycle progression of B lymphocytes. , 1994, Immunology today.
[31] G. L. Wilson,et al. Molecular mechanisms regulating CD19, CD20 and CD22 gene expression. , 1994, Immunology today.
[32] M. Ferguson,et al. Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. , 1993, The Biochemical journal.
[33] T. Tedder,et al. Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes. , 1988, The Journal of biological chemistry.
[34] E. Clark,et al. The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. , 1985, Journal of immunology.
[35] D.,et al. Regression Models and Life-Tables , 2022 .